期刊论文详细信息
Journal of Nanobiotechnology
Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism
Research
Jie Chen1  Qinyan Yang2  Xiaolun Huang2  Jin Shang2  Chunyou Lai2  Yuxin Liang2  Su Yan2  Tianhang Feng2  Deyuan Zhong2  Zonglin Dai2  Zilong Zhang2  Haibo Zou2  Ying Shi2  Yutong Yao2  Yuhao Su2  Lelin Sun3 
[1] Department of Core laboratory, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, 610072, Chengdu, Sichuan, China;Liver Transplantation Center and HBP Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital Affiliate to University of Electronic Science and Technology of China, 610042, Chengdu, Sichuan, China;School of Medicine, University of Electronic Science and Technology of China, 610054, Chengdu, Sichuan, China;School of Medicine, University of Electronic Science and Technology of China, 610054, Chengdu, Sichuan, China;
关键词: Liver fibrosis;    Human adipose mesenchymal stem cells;    Exosomes;    Metabolomics;    Choline;   
DOI  :  10.1186/s12951-023-01788-4
 received in 2022-09-04, accepted in 2023-01-17,  发布年份 2023
来源: Springer
PDF
【 摘 要 】

Liver fibrosis is a chronic liver disease with the presence of progressive wound healing response caused by liver injury. Currently, there are no approved therapies for liver fibrosis. Exosomes derived from human adipose mesenchymal stem cells (hADMSCs-Exo) have displayed a prominent therapeutic effect on liver diseases. However, few studies have evaluated therapeutic effect of hADMSCs-Exo in liver fibrosis and cirrhosis, and its precise mechanisms of action remain unclear. Herein, we investigated anti-fibrotic efficacy of hADMSCs-Exo in vitro and in vivo, and identified important metabolic changes and the detailed mechanism through transcriptomic and metabolomic profiling. We found hADMSCs-Exo could inhibit the proliferation of activated hepatic stellate cells through aggravating apoptosis and arresting G1 phase, effectively inhibiting the expression of profibrogenic proteins and epithelial-to-mesenchymal transition (EMT) in vitro. Moreover, it could significantly block collagen deposition and EMT process, improve liver function and reduce liver inflammation in liver cirrhosis mice model. The omics analysis revealed that the key mechanism of hADMSCs-Exo anti-hepatic fibrosis was the inhibition of PI3K/AKT/mTOR signaling pathway and affecting the changes of metabolites in lipid metabolism, and mainly regulating choline metabolism. CHPT1 activated by hADMSCs-Exo facilitated formation and maintenance of vesicular membranes. Thus, our study indicates that hADMSCs-Exo can attenuate hepatic stellate cell activation and suppress the progression of liver fibrosis, which holds the significant potential of hADMSCs-Exo for use as extracellular nanovesicles-based therapeutics in the treatment of liver fibrosis and possibly other intractable chronic liver diseases.Graphical Abstract

【 授权许可】

CC BY   
© The Author(s) 2023

【 预 览 】
附件列表
Files Size Format View
RO202305119473495ZK.pdf 11051KB PDF download
41116_2022_35_Article_IEq452.gif 1KB Image download
Fig. 5 36KB Image download
41116_2022_35_Article_IEq503.gif 1KB Image download
41116_2022_35_Article_IEq525.gif 1KB Image download
Fig. 2 288KB Image download
41116_2022_35_Article_IEq575.gif 1KB Image download
41116_2022_35_Article_IEq659.gif 1KB Image download
Fig. 6 169KB Image download
Fig. 10 507KB Image download
MediaObjects/12888_2022_4438_MOESM1_ESM.jpg 573KB Other download
【 图 表 】

Fig. 10

Fig. 6

41116_2022_35_Article_IEq659.gif

41116_2022_35_Article_IEq575.gif

Fig. 2

41116_2022_35_Article_IEq525.gif

41116_2022_35_Article_IEq503.gif

Fig. 5

41116_2022_35_Article_IEq452.gif

【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  • [28]
  • [29]
  • [30]
  • [31]
  • [32]
  • [33]
  • [34]
  • [35]
  • [36]
  • [37]
  • [38]
  • [39]
  • [40]
  • [41]
  • [42]
  • [43]
  • [44]
  • [45]
  • [46]
  • [47]
  • [48]
  • [49]
  • [50]
  • [51]
  • [52]
  • [53]
  • [54]
  • [55]
  • [56]
  • [57]
  • [58]
  • [59]
  • [60]
  • [61]
  • [62]
  • [63]
  • [64]
  • [65]
  文献评价指标  
  下载次数:25次 浏览次数:1次